1 Department of Respiraology, The Second Affiliated Hospital of Nantong University, Nantong, China.
2 Biochemistry laboratory, The Second Affiliated Hospital of Nantong University, Nantong, China.
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819872271. doi: 10.1177/1533033819872271.
Lung cancer is one of the most common malignant tumors in humans. Finding a highly sensitive and specific marker is very important. This study investigated the clinical significance of epidermal growth factor in exhaled breath condensate and serum of patients with non-small cell lung cancer.
From October 17, 2013, to June 5, 2017, exhaled breath condensate and blood samples from 155 patients with non-small cell lung cancer, 63 patients with benign pulmonary nodules, and 115 healthy controls were collected using a breath condenser. Each sample was analyzed by enzyme-linked immunosorbent assay.
Epidermal growth factor level in the exhaled breath condensate from the non-small cell lung cancer group (197.86 ± 60.67 pg/mL) was higher than that in the healthy group (124.75 ± 36.09 pg/mL), < .05. Epidermal growth factor level in the exhaled breath condensate of the smoking group (208.85 ± 40.94 pg/mL) was higher than that of the nonsmoking group (185.52 ± 36.88 pg/mL), < .05. Epidermal growth factor level in the exhaled breath condensate in phases III and IV of non-small cell lung cancer group (212.17 ± 35.41 pg/mL) was higher than that in phases I and II (173.91 ± 38.08 pg/mL), < .05. Epidermal growth factor level in the exhaled breath condensate of the death group (241.05 ± 27.19 pg/mL) was higher than that of the survival group (188.75 ± 37.07 pg/mL), < .05. The epidermal growth factor exhaled breath condensate levels were positively correlated with the serum epidermal growth factor levels with a correlation coefficient of 0.495 ( < .05). The sensitivity and specificity of epidermal growth factor exhaled breath condensate test were 80.0% and 89.6%, respectively.
The detection of epidermal growth factor level in exhaled breath condensate exhibits is important in the diagnosis, disease monitoring, and prognosis of non-small cell lung cancer.
肺癌是人类最常见的恶性肿瘤之一。寻找高度敏感和特异的标志物非常重要。本研究探讨了表皮生长因子在非小细胞肺癌患者呼出气冷凝液和血清中的临床意义。
2013 年 10 月 17 日至 2017 年 6 月 5 日，采用呼吸冷凝装置收集 155 例非小细胞肺癌患者、63 例良性肺结节患者和 115 例健康对照者的呼出气冷凝液和血样。采用酶联免疫吸附法分析各样本。
非小细胞肺癌组呼出气冷凝液中表皮生长因子水平（197.86±60.67 pg/mL）高于健康对照组（124.75±36.09 pg/mL），差异有统计学意义（ <.05）。吸烟组呼出气冷凝液中表皮生长因子水平（208.85±40.94 pg/mL）高于不吸烟组（185.52±36.88 pg/mL），差异有统计学意义（ <.05）。非小细胞肺癌Ⅲ+Ⅳ期患者呼出气冷凝液中表皮生长因子水平（212.17±35.41 pg/mL）高于Ⅰ+Ⅱ期患者（173.91±38.08 pg/mL），差异有统计学意义（ <.05）。死亡组呼出气冷凝液中表皮生长因子水平（241.05±27.19 pg/mL）高于生存组（188.75±37.07 pg/mL），差异有统计学意义（ <.05）。呼出气冷凝液中表皮生长因子水平与血清中表皮生长因子水平呈正相关，相关系数为 0.495（ <.05）。呼出气冷凝液表皮生长因子检测的敏感性和特异性分别为 80.0%和 89.6%。
呼出气冷凝液中表皮生长因子水平的检测对非小细胞肺癌的诊断、疾病监测和预后具有重要意义。
